ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Using cluster analysis to investigate consumption patterns in cases positive to ketamine: a national 7-year study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The use of ketamine has increased; however, actual consumption patterns and ketamine-related deaths remain poorly understood. This study aimed to (1) cluster the consumption patterns of individuals who consume ketamine and (2) investigate their associations with manner and cause of death. A retrospective study was conducted on all cases positive to ketamine at death, retrieved from the Institute of Forensic Medicine between 2013 and 2019. A total of 414 individuals tested positive for ketamine in various samples, including blood, pleural effusion, hair, and others, with 294 individuals having detectable ketamine in their blood samples, which were subsequently clustered. The most prevalent patterns identified were ketamine plus alcohol (49.5%), ketamine plus new psychoactive substances (39.1%), and ketamine plus methamphetamine (24.4%). Drug intoxication was the most reported cause of death, followed by traffic accidents. Cluster 1 exhibited moderate ketamine concentrations (1.7 µg/mL), a high prevalence of polydrug use (85%), and an increased risk of suicide. Cluster 4 displayed very low ketamine concentrations (0.13 µg/mL) but similarly high rates of polydrug use (85%) and an elevated risk of accidental death. The concurrent use of ketamine and alcohol, primarily categorized within cluster 3, accounted for nearly half of the deaths resulting from drug intoxication or traffic accidents. Our study underscores the potential dangers of using ketamine as one of multiple substances. Our study also emphasized the critical role that consumption patterns and dosages play in determining the potential lethal outcomes associated with ketamine. In the future, medical applications of ketamine must consider patients' use of other substances and inform them of the associated risks.
Indexed as
Identifiers
40085215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.